CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, announced the successful completion of the Phase l clinical program for Tyrima(TM), its lead candidate for the treatment of depression and anxiety. Tyrima is a selective and reversible member of a novel class of drugs known as RIMAs, or reversible inhibitors of monoamine oxidase A.

More: continued here

This entry was posted on Tuesday, January 29th, 2008 at 7:01 pm and is filed under Depression. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.